Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

4.680 -0.070 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,239
Open 4.850
Bid (Size) 4.400 (5)
Ask (Size) 5.180 (1)
Prev. Close 4.750
Today's Range 4.620 - 4.850
52wk Range 2.330 - 6.700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via Globe NewsWire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET 
From Gain Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+44.44%
+44.44%
1 Month
+8.84%
+8.84%
3 Month
+56.26%
+56.26%
6 Month
+44.00%
+44.00%
1 Year
+18.18%
+18.18%

More News

Read More
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
From Gain Therapeutics, Inc.
Via Globe NewsWire
Expert Ratings for Gain Therapeutics
Via Benzinga
Analyst Ratings for Gain Therapeutics
Via Benzinga
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Gain Therapeutics, Inc.
Via Globe NewsWire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
From Gain Therapeutics, Inc.
Via Globe NewsWire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
From Gain Therapeutics, Inc.
Via Globe NewsWire
Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program
Via Benzinga
Gain Therapeutics: Q2 Earnings Insights
Via Benzinga
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
From Gain Therapeutics, Inc.
Via Globe NewsWire
Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Via Benzinga
AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
Recap: Gain Therapeutics Q1 Earnings
Via Benzinga
Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program
Via Benzinga
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
Via Benzinga
Apple To $185? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Gain Therapeutics: Reasons For Optimism
Via Talk Markets
Aggregate Insider Buying Remains Elevated For A Third Week $AMH
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022
Via Benzinga
92 Biggest Movers From Friday
Via Benzinga
55 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.